To the Editor: In their meta-analysis, Dr Natanson and colleagues1 described the hurdles they faced in accessing data from HBOC trials conducted by pharmaceutical companies. Although we agree that more transparency is needed to balance corporate and public interests, we consider it unacceptable to draw definite conclusions based on seemingly incomplete data.
Their review included trials of varying methodologies performed on heterogeneous patients in different settings with various controls. There may not have been statistical heterogeneity, but there was important clinical heterogeneity. For example, a core issue in HBOC trials is the comparator, and it seemed that blood and nonblood controls yielded similar results. However, although 2 large trials2,3 had mixed blood and nonblood controls, their results were incorrectly pooled with those of the remaining 14 trials in the corresponding subgroup analysis. Some supposedly “nonblood” controls may have received blood and vice versa.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.